HCPCS Level II code Q5112 denotes the 10 mg unit of trastuzumab-dttb (Ontruzant), a biosimilar therapeutic used in the treatment of HER2-positive cancers. As a biosimilar alternative to reference trastuzumab products, this code matters nationally for oncology infusion billing, payer coverage policies, and cost-management strategies across hospital outpatient and ambulatory infusion settings. Adoption of biosimilars can affect formulary decisions, site-of-care cost analyses, and prior authorization workflows.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical and billing identity of the product, the typical infusion service setting, and what to expect from payer coverage considerations at a national level. The publication outlines benchmarking points for utilization and unit-level billing, important policy updates affecting biosimilars and oncology drug reimbursement, and clinical context regarding trastuzumab biosimilar use.

This summary is intended to inform coding, billing, and policy teams about the code's purpose, common service locations, and the types of payer policies that most influence reimbursement and access for biosimilar trastuzumab products. Data not available in the input will be noted explicitly where applicable.